which Eli Lilly posted will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products. Apart from this move, the manufacturer stated that as of May 1st it will reduce the list price of an unbranded insulin it sells from $82 to $25 a vial.
It will be interesting to observe whether other insulin-manufacturing companies will follow suit with price reductions. They may have to, as otherwise they could lose a considerable amount of their market share. In addition, it will be intriguing to note how payers and PBMs respond.
Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:
Funny how that works eh?
Now this is top tier news